Anthropic buys stealth biotech AI startup Coefficient Bio in $400M+ stock deal
What's the deal? AnthropicDealroom has a profile for this one. Try Dealroom → has acquired Coefficient Bio, a stealth biotech AI startup, in a stock deal worth just over $400 million. The startup, formally founded only eight months ago and backed by venture firm Dimension, was building AI models for biological research. The team is joining Anthropic's Healthcare and Life Sciences division, led by Eric Kauderer-AbramsDealroom has a profile for this one. Try Dealroom →.
Dimension held roughly half of Coefficient Bio and is reporting a 38,513% internal rate of return on the investment — an extraordinary return on a very short hold.
Why now? Anthropic has been making a series of targeted acquisitions — Bun and Vercept preceded this deal — as it builds out capabilities beyond its core language model business. Healthcare and life sciences represent one of the most commercially promising near-term applications for frontier AI, and acquiring a team already working on AI for biological research accelerates that effort without building from scratch.
The timing also lands on the same day OpenAI announced its acquisition of tech talk show TBPNDealroom has a profile for this one. Try Dealroom → — a contrast that has not gone unnoticed. One company bought a media property; the other bought a science team.
What could go wrong? Coefficient Bio was eight months old and operating in stealth — meaning its technology and research remain largely unverified by the market. At $400 million in stock for a company with no public track record, the acquisition is essentially a bet on the team and thesis rather than proven product. Integration into a large AI lab also carries the usual risk of losing the focused intensity that makes early-stage science teams productive.
The signal: Anthropic's move reflects a broader race among AI labs to own the application layer in high-value sectors. Biology is particularly attractive: the combination of frontier AI and biological data could compress drug discovery timelines dramatically, and the companies that own those capabilities stand to capture enormous value. Dimension's extraordinary return — achieved in under a year — signals just how quickly the market is val uing AI-native science startups. The Coefficient Bio deal suggests that window is already closing.
Sources:
NewComer
TechCrunch
The Information
A.M.
